INTERIM REPORT JAN-MAR 2016

For the January-March period

  · Net sales for the period totaled SEK 32.6 million (33.7).
  · Operating profit (EBIT) for the period was SEK 1.7 million (5.8).
  · Operating margin for the period was 5 percent (17).
  · Earnings after tax for the period amounted to SEK 0.4 million (5.5).
  · Earnings per share, basic and diluted for the period was SEK 0.00 (0.05).

 Significant events in the first quarter and after the end of the reporting
period

  · On February 9, 2016, CareDx, Inc. announced revised terms of its offer to
the shareholders of Allenex AB. The Board of Directors’ recommendation to the
shareholders of Allenex to accept the offer remained unchanged.
  · On April 8, 2016, CareDx, Inc. announced that the offer to the shareholders
of Allenex AB had been accepted by shareholders representing a total of 118 207
862 shares, equivalent to around 98.3 percent of the number of outstanding
shares, and that the offer is unconditional. CareDx intends to initiate
compulsory acquisition of the remaining shares in the company and in conjunction
with this will push for the share to be delisted from NASDAQ Stockholm.

President and CEO Anders Karlsson’s commentary on the first quarter 2016:
“We continue to see an increase in sales in the USA, which was up more than 10
percent in the first quarter compared to last year. It is gratifying that the
investments in market development that we initiated two years ago continue to
drive sales in the company’s single largest market. Although revenues and EBIT
were down overall, it should be noted that the first quarter 2015 was unusually
strong and that Easter this year was in the month of March. After the end of the
reporting period, CareDx Inc. completed the acquisition of Allenex. The combined
company will be able to offer a strong portfolio of diagnostic products
benefitting transplantation both before and after the transplant.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on May 6, 2016, at 12.30 CET.  Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 57 persons are employed in the
Allenex group.